A Clinical Update on Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke

Antiplatelet therapy remains the standard of care in secondary stroke prevention for non-cardioembolic ischemic stroke and transient ischemic attack. We aim to examine the use of antiplatelet agents in secondary prevention through highlighting relevant clinical trials and meta-analyses as well as providing commentary regarding our practice. In the POINT and CHANCE trials, dual antiplatelet therapy reduced recurrent stroke compared to aspirin...